drugset
Drugs / RTS,S/AS01E
last change Oct 2021 re-read 9 days ago

RTS,S/AS01E

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline · The PATH Malaria Vaccine Initiative (MVI)

Trials 1

today NCT01231503 · Ph 2
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01231503 Jan 2011 → Apr 2014 malaria GlaxoSmithKline Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2021-10-06 GlaxoSmithKline GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗
2021-01-27 GlaxoSmithKline GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS01E “Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age.” NCT01231503 ↗
Modality Vaccine “experimental malaria vaccine” NCT01231503 ↗
Route Intramuscular “The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh.” NCT01231503 ↗